Sunshine Biopharma Stock Target Price
| SBFM Stock | USD 1.43 0.01 0.69% |
Fundamental analysis of Sunshine Biopharma allows traders to better anticipate movements in Sunshine Biopharma's stock price by examining its financial health and performance throughout various phases of its business cycle.
Sunshine | Target Price | Build AI portfolio with Sunshine Stock |
Sunshine Target Price Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sunshine Biopharma's direct or indirect competition against its Target Price to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sunshine Biopharma could also be used in its relative valuation, which is a method of valuing Sunshine Biopharma by comparing valuation metrics of similar companies.Sunshine Biopharma is currently under evaluation in target price category among its peers.
Sunshine Fundamentals
| Return On Equity | -0.21 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.14) % | ||||
| Operating Margin | (0.15) % | ||||
| Current Valuation | (660.43 K) | ||||
| Shares Outstanding | 4.56 M | ||||
| Shares Owned By Insiders | 3.16 % | ||||
| Shares Owned By Institutions | 8.26 % | ||||
| Number Of Shares Shorted | 259 K | ||||
| Price To Earning | 1.07 X | ||||
| Price To Book | 0.29 X | ||||
| Price To Sales | 0.18 X | ||||
| Revenue | 34.87 M | ||||
| Gross Profit | 11.05 M | ||||
| EBITDA | (5.15 M) | ||||
| Net Income | (5.13 M) | ||||
| Cash And Equivalents | 41.74 M | ||||
| Cash Per Share | 2.21 X | ||||
| Total Debt | 952.48 K | ||||
| Debt To Equity | 8.98 % | ||||
| Current Ratio | 401.11 X | ||||
| Book Value Per Share | 8.38 X | ||||
| Cash Flow From Operations | (12.53 M) | ||||
| Short Ratio | 0.36 X | ||||
| Earnings Per Share | (5.76) X | ||||
| Target Price | 140.0 | ||||
| Number Of Employees | 52 | ||||
| Beta | 1.24 | ||||
| Market Capitalization | 6.51 M | ||||
| Total Asset | 30.56 M | ||||
| Retained Earnings | (69.04 M) | ||||
| Working Capital | 19.65 M | ||||
| Current Asset | 23 K | ||||
| Current Liabilities | 277 K | ||||
| Net Asset | 30.56 M |
About Sunshine Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sunshine Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sunshine Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sunshine Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Sunshine Biopharma Piotroski F Score and Sunshine Biopharma Altman Z Score analysis. To learn how to invest in Sunshine Stock, please use our How to Invest in Sunshine Biopharma guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sunshine Biopharma. If investors know Sunshine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sunshine Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.76) | Revenue Per Share | Quarterly Revenue Growth 0.18 | Return On Assets | Return On Equity |
The market value of Sunshine Biopharma is measured differently than its book value, which is the value of Sunshine that is recorded on the company's balance sheet. Investors also form their own opinion of Sunshine Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Sunshine Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sunshine Biopharma's market value can be influenced by many factors that don't directly affect Sunshine Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sunshine Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sunshine Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sunshine Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.